Roche bulks up in gene therapy and hemophilia with $4.3bn Spark buyout

Late-to-the-game Roche has finally made a move in gene therapy, one of the biopharma industry’s most sought-after and expensive classes of medications. And it’s a move that will vault the Swiss drugmaker ahead of the pack. Roche is shelling out $4.3 billion to take in Spark Therapeutics, securing a leading spot in the hot gene […]